FDA approves Rocket's gene therapy KRESLADI for severe LAD-I; Rare Pediatric PRV granted

ROCKET PHARMACEUTICALS, INC.

KRESLADI (marnetegragene autotemcel) approved for pediatric severe LAD-I with no HLA-matched sibling donor.
First FDA-approved gene therapy for severe LAD-I; accelerated approval based on CD18/CD11a expression.
FDA granted Rocket a Rare Pediatric Disease Priority Review Voucher; company plans to evaluate monetization.
Company to host investor conference call March 27 at 8:30 AM ET.
Phase 1/2 study principal investigator Donald Kohn, M.D., highlights years of research culminating in approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.